Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28290649 | 0.90 | NOTUM (0.41) | SIGMAR1HTR2CALDH1A1HPGDMEN1 | |
| SCHEMBL15506531 | 0.84 | MEN1 (0.39) | MEN1KMT2AHTR1AHTR7NISCH | |
| SCHEMBL27604816 | 0.76 | NISCH (0.41) | NISCH | |
| SCHEMBL10230468 | 0.66 | ALDH1A1 (0.39) | ALDH1A1HPGDMEN1KMT2AALOX15 | |
| Biphenyl SCHEMBL2101341 | 0.62 | ALDH1A1 (0.90) | ALDH1A1HSD17B10 | |
| SCHEMBL7541231 | 0.62 | — | — | |
| Biphenyl SCHEMBL1358618 | 0.58 | ALDH1A1 (1.00) | ALDH1A1HSD17B10 | |
| Biphenyl SCHEMBL28890607 | 0.58 | ALDH1A1 (1.00) | ALDH1A1HSD17B10 | |
| Biphenyl SCHEMBL2548048 | 0.58 | ALDH1A1 (1.00) | ALDH1A1HSD17B10 | |
| Biphenyl SCHEMBL164 | 0.58 | ALDH1A1 (1.00) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105308026-B | Cyclic azine compound, manufacturing method with adamantyl and using the compound as the organic electroluminescent device of constituent | 东曹株式会社 | 2018-12-21 | — | — | CN | disclosed |
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2014014310-A1 | A NOVEL COMBINATION OF A HOST COMPOUND AND A DOPANT COMPOUND AND AN ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2014-01-23 | — | — | WO | disclosed |
| US-8610998-B2 | Coloured organic electrophoretic particles | BASF SE (DE) | 2013-12-17 | — | — | US | disclosed |
| CN-101484537-B | Coloured organic electrophoretic particles | CIBA HOLDING INC | 2013-07-17 | — | — | CN | disclosed |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8080536-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7816345-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| CN-101484537-A | Coloured organic electrophoretic particles | CIBA HOLDING INC (CH) | 2009-07-15 | — | — | CN | disclosed |
| EP-1634886-A2 | Novel phosphorus-containing prodrug | Metabasis Therapeutics, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-05-12 | — | — | US | disclosed |
| US-6831083-B2 | For therapy and prophylaxis of cerebral ischemia (cerebral infarct and brain edema), sequela of cerebral ischemia, cephalotrauma, glaucoma, retinopathy, epilepsy and amyotrophic lateral sclerosis (ALS), all caused by glutamic acid toxicity | MITSUI CHEMICALS, INC. (JP) | 2004-12-14 | — | — | US | disclosed |
| US-6752981-B1 | CYCLIC PHOSPH(ORAMID)ATE PRODRUGS HAVING ALCOHOL, AMINE, ORTHIOL GROUPS ATTACHED TO THE PHOSPHORUS IN THE C3N2P OR C3O2P RING | METABASIS THERAPEUTICS, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20030149046-A1 | Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1270567-A1 | PYRAZOLINE DERIVATIVES OR TETRAHYDROPYRIDAZINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1210354-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | Metabasis Therapeutics, Inc. (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001018013-A1 | PRODRUGS FOR LIVER SPECIFIC DRUG DELIVERY | METABASIS THERAPEUTICS, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149046-A1 | Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof | SLC1A2, SLC1A1, SLC1A3 | SIGMAR1 3128/4885HTR2C 2262/4885ALDH1A1 330/4885 |
| US-20050101775-A1 | Cyclic phosph(oramid)ate prodrugs having alcohol, amine, orthiol groups attached to phosphorus; camptothecins; pharmacodynamic half-life; diagnostic imaging | PYGL, PHOSPHO1, OAT | SIGMAR1 819/4885HTR2C 3727/4885ALDH1A1 294/4885 |
| US-20110009356-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | SIGMAR1 689/4885HTR2C 4337/4885ALDH1A1 2369/4885 |
| US-20120093729-A1 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | PYGL, ALPI, SLC10A1 | SIGMAR1 689/4885HTR2C 4337/4885ALDH1A1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.